OPKO Health (OPK) investor relations material

Company overview and strategic focus

• Transitioning from diagnostics to a pharmaceutical and biotech focus, with a strong innovation backbone from the ModeX Therapeutics acquisition.

• Well-capitalized with $340 million on the balance sheet, supporting R&D and shareholder returns.

ModeX multispecific antibody platform

• Platform enables creation of antibodies with up to six specificities, maintaining natural antibody architecture for robust manufacturing.

• Engineering advances simplify manufacturing and improve scalability.

• Platform is plug-and-play and highly robust.

MDX-2001 tetraspecific T-cell engager

• Over 30 patients dosed in phase I; focus on optimizing dose and transitioning to subcutaneous administration for improved safety and convenience.

• No clinically significant cytokine release syndrome or ICANS observed; dosing schedule modified to minimize side effects.

• Subcutaneous dosing trials planned to start late this year, with phase I-B expected next year.

• Data update later this year will focus on safety, immune activation, and dose response; efficacy signals in solid tumors to be explored in phase I-B.